Deciphering the role of Krüppel-like factors (KLFs) polymorphisms in hepatocellular carcinoma: A narrative review

Authors

  • Humaira Bibi Faculty of Rehabilitation and Allied health Sciences (FRAHS), Riphah International University, Rawalpindi.
  • Zainab Nisar Qureshi Government College University, Lahore
  • Nida Tariq Dept of Medical Laboratory Technology (MLT), Rawalpindi Medical University, Rawalpindi.
  • Iqra Zareef Dept of Medical Laboratory Technology (MLT), Rawalpindi Medical University, Rawalpindi.
  • Ali Haider Medical Laboratory Technology. University of Southern Punjab Multan.

DOI:

https://doi.org/10.53992/njns.v11i3.349

Keywords:

Hepatocellular Carcinoma (HCC), Krüppel-Like Factors (Klfs), KLF-15, KLF-6, Biomarker, Gene Regulation

Abstract

The liver cancer especially the hepatocellular carcinoma (HCC) is a significant health burden worldwide as it is a disease with high incidence, late diagnosis, and poor prognosis. Hepatitis B and C infection, cirrhosis, and metabolic disorders are chronic liver diseases that play a major role in the development of HCC. Recent developments in the field of molecular biology have emphasized the significance of genetic and epigenetic changes in the pathogenesis of HCC. These include Krüppel-like factors (KLFs), a family of zinc finger transcription factors that have been found to be important regulators of cellular processes such as proliferation, apoptosis, differentiation, and metabolism. This review is conferred to KLF polymorphisms, especially KLF6 and KLF15, and their role in the molecular pathogenesis of liver cancer. It has been indicated that KLF expression and activity changes aid tumour initiation, progression, and metastasis by affecting key signalling pathways including Wnt/ 2 -catenin, TERT, and TP53. KLF polymorphisms can disrupt the regulatory functions of KLF leading to enhanced growth, reduction in death and metastasis. In addition, these genetic mutations have potential applications as early diagnostic, prognostic, and risk markers for HCC. The study also reviews therapeutic strategies targeting the KLF pathway using approaches such as gene therapy, CRISPR-Cas9 gene editing, and drug targeting. While the findings are encouraging, there are some remaining issues, including conflicting study findings, lack of functional analyses, and genetic diversity. In general, knowledge of the role of KLF polymorphisms can offer useful information on the biology of liver cancer and some new opportunities in the field of personalized diagnosis and targeted treatment, which may lead to better clinical outcomes in patients with HCC.

References

Ullah R, Siraj M, Iqbal J, Abbasi BA. Potential of curcumin and its derivatives, modern insights on the anticancer properties: a comprehensive overview. Cell Mol Biol (Noisy-le-grand). 2026;81(1-2):1–20.

Akkız H, Gieseler RK, Canbay A. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells. Int J Mol Sci. 2024;25(14):7873.

Wang S, Ma Z, Lv L, Yu Q, Liu S, Lu Y. Tumor microenvironment and metabolic reprogramming: Unraveling the complex interplay in gastrointestinal tumor liver metastasis. Crit Rev Oncol Hematol. 2025; 205:105001.

Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, et al. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cell Mol Immunol. 2022;11(5):1357–1370.

Butt MA, Aby ES, Debes JD. The

global epidemiology of hepatocellular carcinoma. Hepatol Commun. 2026; 10(5):e0932.

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606.

Wang Y, Li Y, Yang L, Zhang Z, Liu Z, Li M, et al. Global burden of liver cancer from 1990 to 2021 and 20-year projections: findings from the global burden of disease study 2021. Int J Surg. 2026;112(7):13190.

Ghazy RM, Gebreal A, Saidouni A, Ahmed HAA, Kamal A, Osman AY. Liver Cancer Incidence, Mortality, and Future Trajectories in Egypt (1990–2030): A Global Burden of Disease Analysis. Front Trop Dis. 2024; 5:1356894.

Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864–884.

Wazir H, Abid M, Essani B, Saeed H, Khan MA, Nasrullah F, et al. Diagnosis and treatment of liver disease: current trends and future directions. Cureus. 2023;15(12):e49920.

Alawyia B, Constantinou C. Hepatocellular carcinoma: a narrative review on current knowledge and future prospects. Curr Opin Oncol. 2023; 24(7):711–724.

Manzari‐Tavakoli A, Babajani A, Tavakoli MM, Safaeinejad F, Jafari A. Integrating natural compounds and nanoparticle‐based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy. Cell Prolif. 2024;13(5):e7010.

Guo Q, Zhu X, Beeraka NM, Zhao R, Li S, Li F, et al. Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data. Sci Rep. 2024;14(1):28131.

Carlos AF, Josephs KA. The role of clinical assessment in the era of biomarkers. Nat Rev Neurol. 2023;20(4):1001–1018.

Jauhar MA. Unraveling the Role of a Drosophila Zinc Finger Transcription Factor in Epigenetic Cellular Memory [dissertation]. Lahore: Lahore University of Management Sciences; 2022.

Bieker JJ, Philipsen S. Erythroid Krüppel-like factor (KLF1): a surprisingly versatile regulator of erythroid differentiation. Transcription. 2014;5(4):e989785.

Shi Y, Yao M, Shen S, Wang L, Yao D. Abnormal expression of Krüppel-like transcription factors and their potential values in lung cancer. Heliyon. 2024;10(7):e28654.

Eni-aganga I. Kruppel-Like Factor 6 Promotes Specificity Protein 1-Mediated Prolidase Transcription During Transforming Growth Factor-β1 Signaling [dissertation]. Nashville: Meharry Medical College; 2024.

Yan C, Hu W, Tu J, Li J, Liang Q, Han S. Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease. Mil Med Res. 2023;21(1):300.

Yerra VG, Drosatos K. Specificity proteins (SP) and Krüppel-like factors (KLF) in liver physiology and pathology. Int J Mol Sci. 2023; 24(5):4682.

Huang L, Xing Y, Ning X, Yu Z, Bai X, Liu L, et al. Roles of Twist1 in lipid and glucose metabolism. Cell Commun Signal. 2023;21(1):270.

Jiang Z, Elsarrag SZ, Duan Q, LaGory EL, Wang Z, Alexanian M, et al. KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Sci Adv. 2022;8(10): eabj2917.

Li L, Feldman B. White adipocytes in subcutaneous fat depots require KLF15 for maintenance in preclinical models. J

Clin Invest. 2024;134(13):e176211.

Chen H, Li LL, Du Y. Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming. Front Pharmacol. 2023;14:1115226.

Dilation FF, sDPP4 Soluble. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone. Pharmacol Rep. 2023;75(2):412–422.

Fang R, Sha C, Xie Q, Yao D, Yao M. Alterations of Krüppel-like factor signaling and potential targeted therapy for hepatocellular carcinoma. Anti-Cancer Agents Med Chem. 2025;25(2):75–85.

Umbaugh D, Nguyen N, Guerrero GS, Villanueva C, Hagenbuch B, Ramachandran A, et al. Hepatocyte senescence is initiated through a Klf6-p21 mechanism which mediates the production of Cxcl14, a novel prognostic biomarker of acute liver failure. J Pharmacol Exp Ther. 2023;385(3):226.

Marin JJ, Reviejo M, Soto M, Lozano E, Asensio M, Ortiz-Rivero S, et al. Impact of alternative splicing variants on liver cancer biology. Cancers. 2021;14(1):18.

Hu K, Zheng QK, Ma RJ, Ma C, Sun ZG, Zhang N. Krüppel-like factor 6 splice variant 1: an oncogenic transcription factor involved in the progression of multiple malignant tumors. Front Cell Dev Biol. 2021;9:661731.

Zhang J, Zhao R, Yang P, Zhu Y, Zhu B. KLF family of proteins in gastrointestinal tumors. Oncol Lett. 2026;31(6):237.

Ghouse J, Gellert-Kristensen H, O’Rourke CJ, Seidelin AS, Thorleifsson G, Sveinbjörnsson G, et al. Genome-wide meta-analysis identifies nine loci to be associated with higher risk of hepatocellular carcinoma development. J Hepatol. 2025;82(3): 456–465.

Sadasivam N, Kim YJ, Radhakrishnan K, Kim DK. Oxidative stress, genomic integrity, and liver diseases. Molecules. 2022;27(10):3159.

Li Y, Li L, Zhang Y, Lu J, Tang X, Bi C, et al. Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatment. Translational Metabolic Health and Disease.2025;16:20420188251321602.

Crawford JM, Bioulac-Sage P, Hytiroglou P. Structure, function and pathology of the liver. In: E-Book. 2022. p. 1.

Panier S, Wang S, Schumacher B. Genome instability and DNA repair in somatic and reproductive aging. Annu Rev Pathol Mech Dis. 2024;19(1):261–290.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.

Idrissi YA, Rajabi MR, Beumer JH, Monga SP, Saeed A. Exploring the impact of the β-catenin mutations in hepatocellular carcinoma: an in-depth review. Cell Cycle. 2024;31: 10732748241293680.

Prime SS, Cirillo N, Parkinson EK. Escape from cellular senescence is associated with chromosomal instability in oral pre-malignancy. Biomedicines. 2023;12(1):103.

Azzam S, Straus A, Senkal C, Sarkar D. Molecular Pathophysiology of Hepatocellular Carcinoma: From Metabolic Inflammation to Therapeutic Targets. Cancers. 2026;18(14):2335.

Tabnak P, Ebrahimnezhad M, HajiEsmailPoor Z. Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy. Cell Death Dis. 2026;17(2):112.

Liu T, Li W, Lu W, Chen M, Luo M, Zhang C, et al. RBFOX3 promotes tumor growth and progression via hTERT signaling and predicts a poor prognosis in hepatocellular carcinoma. Theranostics. 2017;7(12):3138–3154.

Fezza M, Moussa M, Aoun R, Haber R, Hilal G. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1. PLoS One. 2019;14(9):e0223252.

Kotiyal S, Evason KJ. Exploring the interplay of telomerase reverse transcriptase and β-catenin in hepatocellular carcinoma. Cancers. 2021;13(16):4202.

Xie B, Cao Y, Li W, Chen R, Zhou Q, Xie X. Nuclear β-catenin: molecular regulation, challenges and therapeutic opportunities. Cell Commun Signal. 2025;24(1):39.

Groenewald W, Lund AH, Gay DM. The role of WNT pathway mutations in cancer development and an overview of therapeutic options. Cancers. 2023;12(7):990.

Wu Z, Wang Z, Zheng D, Zheng Y, Jiang Z, Lv J, et al. RELA ablation contributes to progression of hepatocellular carcinoma with TP53R249S mutation and is a potential therapeutic target. Aging (Albany NY). 2025;12(48):e00335.

Désert R, Mebarki S, Desille M, Sicard M, Lavergne E, Renaud S, et al. “Fibrous nests” in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol. 2016;81:195–207.

Rahman MRU, Chen X, Podder A, Xu X. The evolving role of TP53 mutation in hepatocellular carcinoma (HCC). Cell Commun Signal. 2026;24(1):45.

Somaiah N, Tap WD. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Cancer Treat Rev. 2024; 122:102668.

Curylova L. The p53 family proteins in the regulation of sternness in pediatric sarcomas [dissertation]. Prague: Charles University; 2023.

Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106.

Yerra VG, Drosatos K. Specificity proteins (SP) and Krüppel-like factors (KLF) in liver physiology and pathology. Int J Mol Sci. 2023; 24(5):4682.

Kanyomse Q, Le X, Tang J, Dai F, Mobet Y, Chen C, et al. KLF15 suppresses tumor growth and metastasis in Triple-Negative Breast Cancer by downregulating CCL2 and CCL7. Sci Rep. 2022;12(1):19026.

Li J, Shen J, Zhao Y, Du F, Li M, Wu X, et al. Role of miR-181a-5p in cancer. Int J Oncol. 2023;63(4):108.

Shao Y, Li X, Zhou W, Qian S, Wang L, Fang X. KLF15 attenuates lipopolysaccharide-induced apoptosis and inflammatory response in renal tubular epithelial cells via pparδ. Shock. 2024;62(4):574–581.

Huang Y, Wang Z, Li B, Ke L, Xiong Y, Zhang Y. Loss of KLF15 impairs endometrial receptivity by inhibiting EMT in endometriosis. J Endocrinol. 2024;261(2):e230345.

Jiang W, Liu L, Wang M, Li X, Zhou T, Hou X, et al. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Cell Mol Life Sci. 2024; 81(1):417.

Lin G, Liu X, Cong C, Xu L. Prognostic significance of long noncoding RNA TTN‐AS1 in various malignancies. Cancer Rep. 2023;6(10):e1876.

Shi Y, Yao M, Shen S, Wang L, Yao D. Abnormal expression of Krüppel-like transcription factors and their potential values in lung cancer. Heliyon. 2024;10(7):e28654.

Da Silva Paiva NA. The role of transcription factor KLF15 in the etiopathogenesis of biliary cancer: new diagnostic, prognostic and therapeutic strategy [dissertation]. Porto:

University of Porto; 2022.

Zhao X, Chen L, Wu J, You J, Hong Q, Ye F. Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis. Biol Direct. 2021;16(1):1–11.

Yoda T, McNamara KM, Miki Y, Onodera Y, Takagi K, Nakamura Y, et al. KLF15 in breast cancer: a novel tumor suppressor? Cell Oncol. 2015;38:227–235.

Liu Y, Cheng T, Du Y, Hu X, Xia W. LncRNA LUCAT1/miR-181a-5p axis promotes proliferation and invasion of breast cancer via targeting KLF6 and KLF15. BMC Mol Cell Biol. 2020;21(1):1–11.

Gonzalez-Avila G, Sommer B, García-Hernández AA, Ramos C. Matrix metalloproteinases’ role in tumor microenvironment. In: Tumor Microenvironment: Extracellular Matrix Components–Part A. 2020. p. 97–131.

Kotsari M, Dimopoulou V, Koskinas J, Armakolas A. Immune system and hepatocellular carcinoma (HCC): new insights into HCC progression. Int J Mol Sci. 2023;24(14):11471.

Xiang T, Yang C, Deng Z, Sun D, Luo F, Chen Y. Krüppel‐like factors family in health and disease. MedComm. 2024;5(9):e723.

He Z, He J, Xie K. KLF4 transcription factor in tumorigenesis. Cell Death Discov. 2023;9(1):118.

Zhang J, Zhao R, Yang P, Zhu Y, Zhu B. KLF family of proteins in gastrointestinal tumors. Oncol Lett. 2026;31(6):1–20.

Chen XQ, Ma J, Xu D, Xiang ZL. Comprehensive analysis of KLF2 as a prognostic biomarker associated with fibrosis and immune infiltration in advanced hepatocellular carcinoma. BMC Bioinformatics. 2023;24(1):270.

Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: The virus or the liver? Liver Int. 2023;43:22–30.

Zhao X, Xiao Y, Jiang M, Cao Y. Pharmacological and toxicological roles of Kruppel-like factors (KLFs) in the cardiovascular system: a review. Mol Biol Rep. 2025;52(1):506.

Singh MK, Rallabandi HR, Zhou XJ, YY Q, Zhao ZZ, Gan T, et al. KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasis. Ann Rheum Dis. 2024;83(7):879–888.

Fang R, Sha C, Xie Q, Yao D, Yao M. Alterations of Krüppel-like factor signaling and potential targeted therapy for hepatocellular carcinoma. Anti-Cancer Agents Med Chem. 2025;25(2):75–85.

Zhang Y, Yao C, Ju Z, Jiao D, Hu D, Qi L, et al. Krüppel-like factors in tumors: Key regulators and therapeutic avenues. Front Oncol. 2023;13:1080720.

Wang H, Han J, Dmitrii G, Ning K, Zhang X. KLF transcription factors in bone diseases. J Cell Mol Med. 2024;28(8):e18278.

Zhao Y, Song W, Wang L, Rane MJ, Han F, Cai L. Multiple roles of KLF15 in the heart: underlying mechanisms and therapeutic implications. J Mol Cell Cardiol. 2019;129:193–196.

Xiao Q, Werner J, Venkatachalam N, Boonekamp KE, Ebert MP, Zhan T. Cross-talk between p53 and Wnt signaling in cancer. Biomolecules. 2022;12(3):453.

Sai W, Yang J, Qiu L, Xu M, Yao M, Yao D. Upregulated Krüppel-like factor 5 promotes hepatocellular carcinoma progression by activating Wnt3a signaling. Genes Dis. 2025;12(6): 101685.

Ye L, Wang C, Li A, Li M, Pi Y, Yang J, et al. Targeted next-generation sequencing and long-read HiFi sequencing provide novel insights into clinically significant KLF1 variants. BMC Genomics. 2024;25(1):230.

Trépo E, Caruso S, Yang J, Imbeaud S, Couchy G, Bayard Q, et al. Common

genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncol. 2022;23(1):161–171.

Kingdom R, Wright CF. Incomplete penetrance and variable expressivity: from clinical studies to population cohorts. Front Genet. 2022;13:920390.

Palma-Martínez MJ, Posadas-García YS, Shaukat A, López-Ángeles BE, Sohail M. Evolution, genetic diversity, and health. Nat Med. 2025;31(3):751–761.

Zheng M, Li J, Fang W, Luo L, Ding R, Zeng H, et al. The TNF-α rs361525 and IFN-γ rs2430561 polymorphisms are associated with liver cirrhosis risk: a comprehensive meta-analysis. Front Immunol. 2023;14:1129767.

Jiang Z, Elsarrag SZ, Duan Q, LaGory EL, Wang Z, Alexanian M, et al. KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Sci Adv. 2022; 8(10):eabj2917.

Downloads

Published

23-10-2026

How to Cite

Bibi, H., Qureshi, Z. N., Tariq, N., Zareef, I., & Haider, A. (2026). Deciphering the role of Krüppel-like factors (KLFs) polymorphisms in hepatocellular carcinoma: A narrative review. NUST Journal of Natural Sciences, 11(3), 124–143. https://doi.org/10.53992/njns.v11i3.349